Article
Immunology
ChunYan Yuan
Summary: IL-33 is a cytokine that modulates inflammation and immune responses, primarily associated with the development of Th2 immunological responses. It has been shown to be elevated in various autoimmune disorders, suggesting a role in inducing autoimmunity and inflammatory damage. The IL-33/ST2 axis holds promising potential as a therapeutic target for autoimmune disease treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Oncology
Andrew W. Chung, Anthony J. Kozielski, Wei Qian, Jianying Zhou, Ann C. Anselme, Alfred A. Chan, Ping-Ying Pan, Delphine J. Lee, Jenny C. Chang
Summary: Triple-negative breast cancer (TNBC) patients with mesenchymal stem-like (MSL) subtype have poor response to chemotherapy, while patients with basal-like 1 (BL1) subtype show the best clinical response. Docetaxel activates the MAPK pathway in MSL TNBCs, leading to the release of IL-6 through an IL-1A mediated cascade. Treatment with the humanized IL-6R antibody tocilizumab delays tumor progression in MSL TNBCs.
Article
Rheumatology
Anella Saviano, Adel Abo Manosour, Federica Raucci, Francesco Merlino, Noemi Marigliano, Anna Schettino, Mussarat Wahid, Jenefa Begum, Andrew Filer, Julia E. Manning, Gian Marco Casillo, Marialuisa Piccolo, Maria Grazia Ferraro, Simona Marzano, Pasquale Russomanno, Rosa Bellavita, Carlo Irace, Jussara Amato, Mohammed Alfaifi, Peter Rimmer, Tariq Iqbal, Stefano Pieretti, Valentina Vellecco, Francesco Caso, Luisa Costa, Roberto Giacomelli, Raffaele Scarpa, Giuseppe Cirino, Mariarosaria Bucci, Helen M. McGettrick, Paolo Grieco, Asif Jilani Iqbal, Francesco Maione
Summary: This study identified a novel IL-17A/F-derived peptide and generated a new anti-IL-17 antibody that can effectively reverse the pro-inflammatory actions of IL-17A/F. The antibody showed less off-target effects compared to the current gold-standard biologic. Preclinical and clinical evidence demonstrated the high efficacy and therapeutic potency of the antibody in patients with IMIDs.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Microbiology
Zhaohong Tan, Michelle Meng Huang Mok, Win Mar Soe, Thomas Paulraj Thamboo, Jessamine Geraldine Goh, Qi Hui Sam, Motomi Osato, Sharada Ravikumar, Louis Yi Ann Chai
Summary: The use of tocilizumab in an in-vivo mouse model for invasive candidiasis has shown potential in curbing post-infective inflammatory flare by reducing inflammation and inducing IL-10 production, thus improving short-term survival in patients.
Article
Medicine, General & Internal
Robert Flisiak, Jerzy Jaroszewicz, Magdalena Rogalska, Tadeusz Lapinski, Aleksandra Berkan-Kawinska, Beata Bolewska, Magdalena Tudrujek-Zdunek, Dorota Kozielewicz, Marta Rorat, Piotr Leszczynski, Krzysztof Klos, Justyna Kowalska, Pawel Pabjan, Anna Piekarska, Iwona Mozer-Lisewska, Krzysztof Tomasiewicz, Malgorzata Pawlowska, Krzysztof Simon, Joanna Polanska, Dorota Zarebska-Michaluk
Summary: The study demonstrated the significant impact of tocilizumab on reducing mortality and accelerating clinical improvement in COVID-19 patients with a baseline concentration of IL-6 > 100 pg/mL, particularly those who require oxygen supplementation.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Morry Silberstein
Summary: Vitamin D may be more effective than IL-6 antagonists like tocilizumab in treating COVID-19, as it modulates IL-6 immune responses and potentially reduces pro-inflammatory effects. Current studies indicate a positive therapeutic effect of Vitamin D in COVID-19 patients, providing a strong rationale for its use.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Allergy
Suzanne Cole, Avneet Manghera, Lachrissa Burns, Janine Barrett, Nicole Yager, Hefin Rhys, Andrew Skelton, John Cole, Carl S. Goodyear, Meryn Griffiths, Dominique Baeten, Marta Bertolini, Stevan Shaw, Hussein Al-Mossawi, Asher Maroof
Summary: This study characterizes the regulation of IL-17A and IL-17F in psoriatic disease, showing that IL-17F is elevated preferentially over IL-17A and that each isoform is expressed in distinct cell populations. The study also reveals the plasticity of IL-17A and IL-17F expression, influenced by proinflammatory signaling and anti-inflammatory drugs. Higher IL-17F expression is linked to increased cell proliferation, suggesting the importance of neutralizing both IL-17A and IL-17F in inhibiting IL-17-driven pathology.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Endocrinology & Metabolism
Danny Luan, Benyamin Dadpey, Jessica Zaid, Pania E. Bridge-Comer, Julia H. DeLuca, Wenmin Xia, Joshua Castle, Shannon M. Reilly
Summary: The bidirectional interaction between adipocytes and adipose tissue immune cells is crucial for regulating adipose function, inflammation, and insulin responsiveness. Obesity reduces cAMP-driven IL-6 secretion from adipocytes, but restoring their catecholamine sensitivity can stimulate IL-6 secretion and activate macrophages to promote an anti-inflammatory gene expression pattern.
Review
Biochemistry & Molecular Biology
Matteo Trimarchi, Dorina Lauritano, Gianpaolo Ronconi, Alessandro Caraffa, Carla E. Gallenga, Ilias Frydas, Spyros K. Kritas, Vittorio Calvisi, Pio Conti
Summary: The etiopathogenesis of periodontal disease involves autoimmunity, inflammation affecting periodontal tissues and bone, and dysbiosis of oral microbiota triggering immune responses. Mast cells and cytokines play crucial roles in the inflammatory process in the gingiva.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Rheumatology
Anqi Wang, Linyi Peng, Jiaxin Zhou, Zheng Liu, Hui Lu, Yu Peng, Jieqiong Li, Yunyun Fei, Wen Zhang
Summary: This study investigated the effectiveness and safety of TCZ monotherapy for CP patients at acute active stage. The results showed that after 3 months of TCZ treatment, 27.3% of patients achieved partial remission and 63.6% achieved complete remission, with a total remission rate of 90.9%. All patients reported improvement in clinical symptoms and inflammatory markers decreased to normal levels. Furthermore, 81.8% of patients showed significant shrinkage of perivascular mass.
Article
Pharmacology & Pharmacy
Liping Liao, Wenzhen Dang, Tingting Lin, Jinghua Yu, Tonghai Liu, Wen Li, Senhao Xiao, Lei Feng, Jing Huang, Rong Fu, Jiacheng Li, Liping Liu, Mingchen Wang, Hongru Tao, Hualiang Jiang, Kaixian Chen, Xingxing Diao, Bing Zhou, Xiaoyan Shen, Cheng Luo
Summary: PGK1 plays a role in immunometabolism by influencing metabolic status. The inhibitor DC-PGKI can suppress the activity of PGK1 and alleviate symptoms of inflammatory bowel disease.
ACTA PHARMACEUTICA SINICA B
(2022)
Article
Rheumatology
Dionysis Nikolopoulos, Theodora Manolakou, Alexia Polissidis, Anastasia Filia, George Bertsias, Yassemi Koutmani, Dimitrios T. Boumpas
Summary: Inflammatory mediators are detected in the cerebrospinal fluid of systemic lupus erythematosus patients with central nervous system involvement. The study found that intact blood-brain barrier with microglial activation disrupts the formation of new neurons within the hippocampus in the early stage of the disease. In the later stage, the blood-brain barrier is disrupted, allowing immune components from peripheral blood, especially B-cells, to enter the hippocampus and further augment inflammation.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Giuliana Guggino, Chiara Rizzo, Leila Mohammadnezhad, Marianna Lo Pizzo, Vincenzo Luca Lentini, Diana Di Liberto, Lidia La Barbera, Stefania Raimondo, Mojtaba Shekarkar Azgomi, Ornella Urzi, Onorina Berardicurti, Giuseppina Campisi, Riccardo Alessandro, Roberto Giacomelli, Francesco Dieli, Francesco Ciccia
Summary: The study aimed to investigate the expression of interleukin (IL)-40 in primary Sjogren syndrome (pSS) and pSS-associated lymphomas. The results showed that IL-40 was significantly increased in the lymphocytic infiltrated minor salivary gland of pSS patients and in pSS-associated lymphomas. B cells were found to be the major source of IL-40. In vitro experiments demonstrated that IL-40 stimulation resulted in the release of proinflammatory cytokines. The findings suggest that IL-40 may play a role in pSS pathogenesis and pSS-associated lymphomas.
Article
Clinical Neurology
Xiao Liu, Jingjing Huang, Yuan Jiang, Zhengyu Cao, Maoxiong Wu, Runlu Sun, Zhiteng Chen, Peng Yu, Jianyong Ma, Yangxin Chen, Yuling Zhang, Jingfeng Wang
Summary: This study investigated the inflammatory biomarker profiles of psychological treatment-naive individuals and found that levels of IL-6 and IL-8 were positively correlated with symptoms of depression, suggesting they may play a role in the pathogenesis of psychological disorders. However, these associations were not significant after multiple testing. Larger and longitudinal studies are needed to confirm these findings.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Immunology
Jian Wu, Jiawei Shen, Ying Han, Qinghua Qiao, Wei Dai, Bangshun He, Rongrong Pang, Jun Zhao, Tao Luo, Yanju Guo, Yang Yang, Qiuyue Wu, Weijun Jiang, Jing Zhang, Mingchao Zhang, Na Li, Weiwei Li, Xinyi Xia
Summary: IL-6 levels are closely linked to various indicators and prognosis in COVID-19 patients, serving as a stable marker for inflammation. Treatments like tocilizumab and convalescent plasma therapy can reduce IL-6 levels, alleviate inflammation, and are particularly effective for critically ill patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Gerd R. Burmester, Ernest Choy, Alan Kivitz, Atsushi Ogata, Min Bao, Akira Nomura, Stuart Lacey, Jinglan Pei, William Reiss, Attila Pethoe-Schramm, Navita L. Mallalieu, Thomas Wallace, Margaret Michalska, Herbert Birnboeck, Kay Stubenrauch, Mark C. Genovese
ANNALS OF THE RHEUMATIC DISEASES
(2017)
Article
Immunology
Kosuke Fujimoto, Makoto Kinoshita, Hiroo Tanaka, Daisuke Okuzaki, Yosuke Shimada, Hisako Kayama, Ryu Okumura, Yoki Furuta, Masashi Narazaki, Atsushi Tamura, Shigetsugu Hatakeyama, Masahito Ikawa, Kiichiro Tsuchiya, Mamoru Watanabe, Atsushi Kumanogoh, Sachiko Tsukita, Kiyoshi Takeda
MUCOSAL IMMUNOLOGY
(2017)
Letter
Rheumatology
T. Morita, Y. Shima, A. Kakigano, A. Ogata, A. Kumanogoh
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2017)
Article
Rheumatology
Atsushi Ogata, Yoshiya Tanaka, Tomonori Ishii, Motohide Kaneko, Hiroko Miwa, Shino Ohsawa
MODERN RHEUMATOLOGY
(2018)
Review
Biochemistry & Molecular Biology
Masashi Narazaki, Tadamitsu Kishimoto
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2018)
Review
Rheumatology
Atsushi Ogata, Yasuhiro Kato, Shinji Higa, Kazuyuki Yoshizaki
MODERN RHEUMATOLOGY
(2019)
Review
Pharmacology & Pharmacy
Atsushi Ogata, Yasuhiro Kato, Shinji Higa, Keiji Maeda
EXPERT OPINION ON DRUG DELIVERY
(2019)
Article
Rheumatology
Toshihiro Kishikawa, Yuichi Maeda, Takuro Nii, Daisuke Motooka, Yuki Matsumoto, Masato Matsushita, Hidetoshi Matsuoka, Maiko Yoshimura, Shoji Kawada, Satoru Teshigawara, Eri Oguro, Yasutaka Okita, Keisuke Kawamoto, Shinji Higa, Toru Hirano, Masashi Narazaki, Atsushi Ogata, Yukihiko Saeki, Shota Nakamura, Hidenori Inohara, Atsushi Kumanogoh, Kiyoshi Takeda, Yukinori Okada
ANNALS OF THE RHEUMATIC DISEASES
(2020)
Review
Immunology
Sujin Kang, Masashi Narazaki, Hozaifa Metwally, Tadamitsu Kishimoto
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Letter
Rheumatology
Masashi Okamoto, Shoji Kawada, Hiroshi Shimagami, Naoko Fujii, Kazuki Matsukawa, Nachi Ishikawa, Keisuke Kawamoto, Shinji Higa, Yutaka Ishida, Atsushi Ogata, Yuta Yamaguchi, Takayoshi Morita, Yasuhiro Kato, Atsushi Kumanogoh
ARTHRITIS & RHEUMATOLOGY
(2022)
Review
Pharmacology & Pharmacy
Masashi Narazaki, Tadamitsu Kishimoto
Summary: Clinical evidence suggests that IL-6-targeting therapy is relatively safe but early detection of infectious diseases is crucial. Despite the need for validation through clinical trials, IL-6-targeting therapy is considered a potential treatment option for various refractory immune diseases where it has shown efficacy.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2022)
Article
Rheumatology
Tansri Wibowo, Shoji Kawada, Yutaka Ishida, Yuko Yoshimine, Nachi Ishikawa, Keisuke Kawamoto, Yasuhiro Kato, Shinji Higa, Atsushi Ogata, Keiji Maeda
MODERN RHEUMATOLOGY CASE REPORTS
(2020)
Article
Immunology
Takayoshi Morita, Yoshihito Shima, Kosuke Fujimoto, Hideki Tsuboi, Yukihiko Saeki, Masashi Narazaki, Atsushi Ogata, Atsushi Kumanogoh
INTERNATIONAL IMMUNOLOGY
(2019)
Letter
Rheumatology
Takayoshi Morita, Kosuke Fujimoto, Yoshihito Shima, Atsushi Ogata, Atsushi Kumanogoh
ANNALS OF THE RHEUMATIC DISEASES
(2018)
Article
Rheumatology
Masayuki Nishide, Satoshi Nojima, Daisuke Ito, Hyota Takamatsu, Shohei Koyama, Sujin Kang, Tetsuya Kimura, Keiko Morimoto, Takashi Hosokawa, Yoshitomo Hayama, Yuhei Kinehara, Yasuhiro Kato, Takeshi Nakatani, Yoshimitsu Nakanishi, Takeshi Tsuda, Jeong Hoon Park, Toru Hirano, Yoshihito Shima, Masashi Narazaki, Eiichi Morii, Atsushi Kumanogoh
ANNALS OF THE RHEUMATIC DISEASES
(2017)